Gene ther­a­py side ef­fects prompt search for new de­liv­ery meth­ods

SAN FRAN­CIS­CO — Just a few years since the first gene ther­a­pies be­came avail­able, there has been a shift among small biotechs and large phar­ma com­pa­nies about how to best de­liv­er the edit­ed genes, in par­tic­u­lar re­gard­ing the virus­es and oth­er vec­tors that in­sert gene ther­a­py pay­loads in­to cells.

The goal of these new de­liv­ery tech­niques is a more pre­cise mech­a­nism less like­ly to pro­duce harm­ful side ef­fects, and the shift is like­ly to rip­ple through the sec­tor.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.